# Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)

> **NCT02959944** · PHASE3 · COMPLETED · sponsor: **Pharmacyclics LLC.** · enrollment: 193 (actual)

## Conditions studied

- Chronic Graft Versus Host Disease

## Interventions

- **DRUG:** ibrutinib
- **DRUG:** Placebo
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02959944
- **Lead sponsor:** Pharmacyclics LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-11
- **Primary completion:** 2020-03-27
- **Final completion:** 2021-07-12
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2023-03-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02959944

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02959944, "Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02959944. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*